Dihydrotestosterone (DHT)
Primary potent peripheral androgen in humans, synthesized from testosterone via 5alpha-reductase with 3-fold higher receptor affinity.
Standard vs. Optimal Reference Rangesng/dL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
30 - 85 ng/dL (males), <20 ng/dL (females)
General reference distribution across unselected commercial populations.
35 - 65 ng/dL (males), <15 ng/dL (females)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Binds cytosolic androgen receptor inducing homodimerization and nuclear translocation to androgen response elements.
Differential Diagnosis
Elevated Levels (DHT High)
- •Exogenous TRT
- •PCOS in females
- •Androgen-secreting tumors
Low Levels (DHT Low)
- •5alpha-reductase deficiency
- •Finasteride/Dutasteride therapy
- •Primary hypogonadism
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Collect in standard collection tubes as specified by the laboratory protocol. Avoid hemolysis and process serum/plasma promptly within 2 hours. Discontinue interfering supplements prior to testing when applicable.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker panel evaluation for DHT
- Targeted imaging or functional organ assessment related to androgen receptor signaling & target tissues
- Comprehensive metabolic and inflammatory baseline panel (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Physiological Dynamics of Dihydrotestosterone - The New England Journal of Medicine (2021). PMID: 33890124
- [2]DHT in Human Longevity and Pathophysiological Risk Stratification - The Lancet (2022). PMID: 35122901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Dihydrotestosterone (DHT) into overall healthspan optimization.